Feasibility and acceptability of a primary care liver fibrosis testing pathway centred on the diabetes annual review: PRELUDE1 prospective cohort study protocol
BMJ Open · 2023
DOI: 10.1136/bmjopen-2022-066493 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift BMJ Open, 2023. Verfasst von James Hallimond Brindley und 6 weiteren Autor:innen. Beteiligte Einrichtung: Barts Liver Centre, Queen Mary University of London, London, UK h.brindley@qmul.ac.uk. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Gilead Sciences.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction Non-alcoholic fatty liver disease is the most common chronic liver disease worldwide affecting 20%–25% in the USA and Europe with a 60%–80% lifetime prevalence for people with type 2 diabetes (T2D). Fibrosis has repeatedly been demonstrated to be the major determinant of liver disease morbidity and mortality and there is currently no routine screening for liver fibrosis in at-risk T2D population. Methods and analysis This 12-month prospective cohort study of automated fibrosis testing uses the fibrosis-4 score (FIB-4) in patients with T2D linked to the investigation of hospital-based versus community-based second-tier transient elastography (TE) testing. We plan to include >5000 participants across 10 General Practitioner (GP) practices in East London and Bristol. This will determine the rate of undiagnosed significant liver fibrosis in a T2D population, the feasibility of two-tier liver fibrosis screening using FIB-4 at the diabetes annual review and subsequent TE delivered either in the community or secondary care settings. This will include an intention-to-treat analysis for all those invited to attend for diabetes annual review. A qualitative substudy regarding the acceptability of the fibrosis screening pathway will comprise semistructured interviews/focus groups with primary care staff (GPs and practice nurses), and patients taking part in the wider study. Ethics and dissemination This study received a favourable opinion from the Cambridge East research ethics committee. The results of this study will be disseminated in peer-reviewed scientific journals, conference presentations and local diabetes lay panel meetings. Trial registration number ISRCTN14585543 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Barts Liver Centre, Queen Mary University of London, London, UK h.brindley@qmul.ac.uk.
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
- Barts Liver Centre, Queen Mary University of London, London, UK.
- Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
- Bristol Population Health Science Institute, University of Bristol, Bristol, UK.
ORCID-Profile: James Hallimond Brindley, Stacey Jennings, Matthew Hickman
Förderung
- Gilead Sciences
Zitieren
APA
Brindley, J. H., Abeysekera, K., Hood, G., Jennings, S., Moore, J., Hickman, M., & Alazawi, W. (2023). Feasibility and acceptability of a primary care liver fibrosis testing pathway centred on the diabetes annual review: PRELUDE1 prospective cohort study protocol. BMJ Open. https://doi.org/10.1136/bmjopen-2022-066493
Vancouver
Brindley JH, Abeysekera K, Hood G, Jennings S, Moore J, Hickman M, et al. Feasibility and acceptability of a primary care liver fibrosis testing pathway centred on the diabetes annual review: PRELUDE1 prospective cohort study protocol. BMJ Open. 2023. doi:10.1136/bmjopen-2022-066493
BibTeX
@article{Brindley2023,
author = {Brindley, James Hallimond and Abeysekera, Kushala and Hood, Gill and Jennings, Stacey and Moore, John and Hickman, Matthew and Alazawi, William},
title = {Feasibility and acceptability of a primary care liver fibrosis testing pathway centred on the diabetes annual review: PRELUDE1 prospective cohort study protocol},
journal = {BMJ Open},
year = {2023},
doi = {10.1136/bmjopen-2022-066493}
}
EUVIMED